These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7555523)

  • 1. Prevalence of IDDM in adults in the community.
    Maislos M; Weitzman S
    Diabetes Care; 1995 Jun; 18(6):885-6. PubMed ID: 7555523
    [No Abstract]   [Full Text] [Related]  

  • 2. Are young age and insulin treatment enough to diagnose IDDM?
    Maislos M; Weitzman S
    Diabetes Care; 1997 Apr; 20(4):675-6. PubMed ID: 9097003
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of C-peptide in the classification of diabetes mellitus.
    Wright-Pascoe R; Mills J; Choo-Kang E; Morrison EY
    West Indian Med J; 2000 Jun; 49(2):138-42. PubMed ID: 10948853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM.
    Dupré J; Behme MT; Hramiak IM; McDonald TJ
    Diabetes Care; 1997 Mar; 20(3):381-4. PubMed ID: 9051391
    [No Abstract]   [Full Text] [Related]  

  • 5. Identifying latent autoimmune diabetes in adults in Korea: the role of C-peptide and metabolic syndrome.
    Lee SH; Kwon HS; Yoo SJ; Ahn YB; Yoon KH; Cha BY; Lee KW; Son HY
    Diabetes Res Clin Pract; 2009 Feb; 83(2):e62-5. PubMed ID: 19166794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-peptide and free insulin determinations in type I diabetes; relationships with metabolic control and insulin therapy.
    Taskinen MR; Groop L
    Ann Clin Res; 1984; 16(2):118-27. PubMed ID: 6380385
    [No Abstract]   [Full Text] [Related]  

  • 7. [Insulin and C-peptide in the blood serum of children and adolescents with diabetes mellitus].
    Balabolkin MI; Zubovskiĭ GA; Stuliĭ LA; Domanova VT
    Med Radiol (Mosk); 1980 Jun; 25(6):34-7. PubMed ID: 6993830
    [No Abstract]   [Full Text] [Related]  

  • 8. Glucagon-induced plasma C-peptide response in diabetic patients. Influence of body weight and relationship to insulin requirement.
    Scheen AJ; Castillo MJ; Lefèbvre PJ
    Diabetes Metab; 1996 Dec; 22(6):455-8. PubMed ID: 8985655
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclosporin-A treatment for early insulin-dependent diabetes mellitus: first experience in Israel.
    Kisch ES; Yust I
    Isr J Med Sci; 1989 Jul; 25(7):414-6. PubMed ID: 2759840
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevalence of adult-onset IDDM in the U.S. population.
    Harris MI; Robbins DC
    Diabetes Care; 1994 Nov; 17(11):1337-40. PubMed ID: 7821176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of clinical remission in recent-onset IDDM.
    Hramiak IM; Dupre J; Finegood DT
    Diabetes Care; 1993 Jan; 16(1):125-32. PubMed ID: 8422766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes.
    Davis AK; DuBose SN; Haller MJ; Miller KM; DiMeglio LA; Bethin KE; Goland RS; Greenberg EM; Liljenquist DR; Ahmann AJ; Marcovina SM; Peters AL; Beck RW; Greenbaum CJ;
    Diabetes Care; 2015 Mar; 38(3):476-81. PubMed ID: 25519448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Incidence of insulin dependent diabetes in youth in Israel in 1997: Israel IDDM Registry Study Group for incidence of diabetes between the ages of 0-17].
    Harefuah; 2000 Feb; 138(4):290-4, 343, 342. PubMed ID: 10883114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and clinical characteristics of type I and type II insulin-treated diabetes in the community.
    Maislos M; Bodner-Fishman B; Weitzman S
    Diabetes Care; 1994 Oct; 17(10):1230-1. PubMed ID: 7821154
    [No Abstract]   [Full Text] [Related]  

  • 15. Insulin replacement therapy. Minimizing complications and side effects.
    Fleury-Milfort E
    Adv Nurse Pract; 2008 Nov; 16(11):32-9: quiz 39-40. PubMed ID: 19999054
    [No Abstract]   [Full Text] [Related]  

  • 16. Continuous subcutaneous insulin infusion in adults: glycemic advantage is predicted by venous plasma C-peptide concentrations.
    Rodger NW; Dupre J; Canny CL; Brown WF
    Diabetes Care; 1985; 8(5):447-55. PubMed ID: 3902423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Levels of some auto-antibodies and C-peptide in insulin-treated patients with diabetes mellitus (DM) depending on gender of the patients and disease duration].
    Likhonosov PN; Khalangot ND
    Lik Sprava; 2007; (5-6):50-5. PubMed ID: 18416165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Autoimmune insulitis in patients with type 2 diabetes mellitus A randomized clinical trial in hospitalized patients].
    Martinka E; Rončáková M; Mišániková M; Davani A
    Vnitr Lek; 2016; 62(7-8):521-33. PubMed ID: 27627073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both insulin sensitivity and insulin clearance in children and young adults with type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age.
    Acerini CL; Cheetham TD; Edge JA; Dunger DB
    Diabetologia; 2000 Jan; 43(1):61-8. PubMed ID: 10663217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.